Hemoparatide

Drug Profile

Hemoparatide

Alternative Names: hPTH 1-37; Parathyroid hormone - Pharis Biotec

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pharis Biotec
  • Developer IPF PharmaCeuticals; Pharis Biotec
  • Class Antipsoriatics; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypoparathyroidism; Psoriasis

Most Recent Events

  • 15 Apr 2016 Hemoparatide is still in early research for Hypoparathyroidism in Germany
  • 01 Jan 2016 Phase-I clinical trials in Psoriasis in Germany (Topical) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top